Stocks and Investing Stocks and Investing
Tue, March 7, 2017
Mon, March 6, 2017
Sat, March 4, 2017
Fri, March 3, 2017
Thu, March 2, 2017

Joseph Schwartz Upgraded (SRPT) to Buy and Increased Target to $47 on, Mar 2nd, 2017


Published on 2024-10-25 20:23:41 - WOPRAI, Joseph Schwartz
  Print publication without navigation


Joseph Schwartz of Leerink Swann, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy and Increased Target from $27 to $47 on, Mar 2nd, 2017.

Joseph has made no other calls on SRPT in the last 4 months.



There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, 0 agree with Joseph's Rating of Hold.



This is the rating of the analyst that currently disagrees with Joseph


  • Anupam Rama of "JP Morgan" Initiated at Buy and Held Target at $40 on, Thursday, December 22nd, 2016